[
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Allele\nBC PScov\n\n\n\n1\nA*01:01\n− 0.2952\n\n\n2\nA*02:01\n0.5382\n\n\n3\nA*02:05\n− 0.1039\n\n\n4\nA*03:01\n1.1290\n\n\n5\nA*11:01\n− 0.0594\n\n\n6\nA*23:01\n− 0.1914\n\n\n7\nA*24:02\n0.1594\n\n\n8\nA*25:01\n− 0.1075\n\n\n9\nA*26:01\n− 0.1197\n\n\n10\nA*29:01\n0.0682\n\n\n11\nA*29:02\n− 0.2047\n\n\n12\nA*30:01\n− 0.1013\n\n\n13\nA*30:02\n− 0.0785\n\n\n14\nA*31:01\n0.2128\n\n\n15\nA*32:01\n− 0.0159\n\n\n16\nA*33:01\n− 0.1004\n\n\n17\nA*33:03\n0.0166\n\n\n18\nA*36:01\n− 0.0162\n\n\n19\nA*68:01\n0.0510\n\n\n20\nA*68:02\n− 0.2907\n\n\n21\nB*07:02\n0.3402\n\n\n22\nB*08:01\n0.0555\n\n\n23\nB*13:02\n− 0.0664\n\n\n24\nB*14:01\n− 0.0576\n\n\n25\nB*14:02\n− 0.2176\n\n\n26\nB*15:01\n0.3654\n\n\n27\nB*15:17\n− 0.0292\n\n\n28\nB*15:18\n0.0206\n\n\n29\nB*18:01\n0.1684\n\n\n30\nB*27:02\n0.0699\n\n\n31\nB*27:05\n0.5210\n\n\n32\nB*35:01\n0.2589\n\n\n33\nB*35:02\n− 0.0911\n\n\n34\nB*35:03\n− 0.0715\n\n\n35\nB*35:08\n0.0366\n\n\n36\nB*37:01\n0.0889\n\n\n37\nB*38:01\n− 0.0487\n\n\n38\nB*39:01\n0.0261\n\n\n39\nB*39:06\n0.0478\n\n\n40\nB*40:01\n0.5888\n\n\n41\nB*40:02\n0.1338\n\n\n42\nB*41:01\n0.0567\n\n\n43\nB*41:02\n0.0026\n\n\n44\nB*44:02\n− 0.1702\n\n\n45\nB*44:03\n− 0.3708\n\n\n46\nB*44:05\n0.0159\n\n\n47\nB*45:01\n− 0.0031\n\n\n48\nB*47:01\n0.0071\n\n\n49\nB*49:01\n− 0.1197\n\n\n50\nB*50:01\n− 0.1328\n\n\n51\nB*51:01\n0.3583\n\n\n52\nB*52:01\n0.1448\n\n\n53\nB*55:01\n− 0.0422\n\n\n54\nB*56:01\n0.0712\n\n\n55\nB*57:01\n− 0.0430\n\n\n56\nB*58:01\n0.0435\n\n\n57\nC*01:02\n0.2524\n\n\n58\nC*03:03\n0.5642\n\n\n59\nC*04:01\n− 0.1252\n\n\n60\nC*05:01\n− 0.1708\n\n\n61\nC*06:02\n− 0.3901\n\n\n62\nC*07:01\n0.2317\n\n\n63\nC*07:02\n0.3645\n\n\n64\nC*07:04\n− 0.0421\n\n\n65\nC*12:02\n0.0610\n\n\n66\nC*12:03\n− 0.2835\n\n\n67\nC*14:02\n− 0.0862\n\n\n68\nC*15:02\n− 0.1222\n\n\n69\nC*16:01\n− 0.3437\n\n\n\nOpen in a new tabImmunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Immunogenicity of virus proteins for HLA Class I alleles\nImmunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Gene A\nGene B\nGene C\n\n\nAllele\nI\nAllele\nI\nAllele\nI\n\n\n\n\nA*68:02\n10.45\nB*56:01\n9.79\nC*03:03\n12.81\n\n\nA*02:05\n10.34\nB*55:01\n9.52\nC*12:03\n12.39\n\n\nA*32:01\n8.8\nB*14:01\n9.30\nC*12:02\n12.16\n\n\nA*25:01\n8.2\nB*14:02\n9.30\nC*01:02\n12.04\n\n\nA*30:01\n7.74\nB*35:02\n9.16\nC*16:01\n11.87\n\n\nA*02:01\n7.26\nB*52:01\n8.81\nC*15:02\n11.27\n\n\nA*26:01\n6.85\nB*13:02\n8.62\nC*14:02\n10.25\n\n\nA*23:01\n6.21\nB*35:03\n8.58\nC*07:04\n10.17\n\n\nA*24:02\n5.77\nB*15:18\n8.34\nC*04:01\n9.94\n\n\nA*33:01\n5.41\nB*35:08\n8.29\nC*05:01\n9.21\n\n\nA*31:01\n5.20\nB*35:01\n8.28\nC*07:02\n8.83\n\n\nA*33:03\n5.08\nB*39:01\n8.07\nC*06:02\n8.74\n\n\nA*68:01\n4.78\nB*38:01\n7.56\nC*07:01\n8.13\n\n\nA*29:01\n4.66\nB*39:06\n7.47\n\n\n\nA*29:02\n4.66\nB*07:02\n7.16\n\n\nA*36:01\n4.41\nB*51:01\n6.63\n\n\nA*01:01\n3.93\nB*47:01\n6.55\n\n\nA*30:02\n3.80\nB*15:17\n6.50\n\n\nA*11:01\n3.54\nB*18:01\n6.09\n\n\nA*03:01\n3.45\nB*37:01\n6.09\n\n\n\n\nB*58:01\n5.73\n\n\nB*15:01\n5.69\n\n\nB*57:01\n5.66\n\n\nB*50:01\n5.10\n\n\nB*49:01\n4.92\n\n\nB*08:01\n4.78\n\n\nB*41:01\n4.56\n\n\nB*45:01\n4.51\n\n\nB*44:03\n4.45\n\n\nB*40:01\n4.43\n\n\nB*40:02\n4.33\n\n\nB*44:02\n4.28\n\n\nB*41:02\n4.08\n\n\nB*44:05\n4.06\n\n\nB*27:05\n3.58\n\n\nB*27:02\n3.47\n\n\n\nOpen in a new tab\nThe combination of 6 alleles with the highest immunogenicity scores are shown in bold.Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Immunogenicity scores varied appreciably among HLA alleles (Fig. 1 and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 2 that HLA allele C had the highest immunogenicity effect (P < 0.001 for both comparisons against genes A and B; two-sided t-test ANOVA), whereas gene B had a higher effect than gene A which, however, did not reach statistical significance (P = 0.057, two-sided t-test, ANOVA).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 4.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "See Table 3 for statistics.Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Colors reflect gradation in PVE. (Data from Table 3).Figure 6.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 7.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "See text for details.Figure 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The sectors of HHV4 and HHV2 (in black) were almost totally overlapping.The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "JCV had the highest PVE (column 3 in Table 3, Fig. 3A), followed by HHV6A (Fig. 3B), HHV5 (Fig. 4A), HHV3 (Fig. 4B), HHV8, and HHV7, whereas HPV, HHV6B, HHV4, and HHV2 had negligible PVEs (all < 1%).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "These groupings of BC-HLA and virus immunogenicity associations are illustrated in Fig. 5 which plots the PVE (Eq. 4) for each virus.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "It can be seen in Fig. 6 that (a) JCV is alone in the upper right quadrant, (b) HHV6A, HH5 and HHV3 are in the lower right quadrant, (c) HHV7 and HHV8 are in a separate cluster also in the lower right quadrant, and (d) all the remaining viruses (HHV1, HHV2, HHV4, HHV6B, and HPV) are tightly clustered together in the upper left quadrant.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "This segregation of PVEs is further exemplified in the dendrogram of Fig. 7, as follows.",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "There are two main branches: (i) branch 1 comprises the 6 viruses with non-negligible association to BC-HLA scores, corresponding to the points on the positive (right) side of the MDS plot of Fig. 6 (clusters a, b, c); and (ii) branch 2 comprises the 5 viruses with negligible contributions (PVE) to BC-HLA scores (corresponding to cluster d in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "Branch 1a comprises two branches (1a1 and 1a2), of which branch 1a1 contains JCV alone (corresponding to cluster a in Fig. 6) and branch 1a2 contains HHV3, HHV5 and HHV6A (corresponding to cluster b in Fig. 6); branch 1b comprises HHV7 and HHV8 (cluster c in Fig. 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The total, combined PVE of the 11 viruses was 44.52%, which means that of the BC-HLA PScov variance, 44.52% was accounted for by the immunogenicities of the 11 virus proteins studied (Fig. 8, left panel).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "The relative contributions to this total by each virus are given in column 4 of Table 3 and illustrated in the pie graph on the right panel in Fig. 8.",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Let K be the number of nonamers that showed positive immunogenicity (score > 0.4); then, K weighted by their average score , would serve as a good estimate of the overall effectiveness of a given allele, I, to induce immunogenicity for a given protein:\n\n\n2\n\nFigure 9.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nThe sliding nonamer window approach used to determine exhaustively in silico the immunogenicity of all possible consecutive nonamers in a protein, illustrated here for human polyoma major capsid protein VP1.The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Therefore, this transformation was applied to I for further analyses:\n\n\n3\n\nFigure 10.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\n(A) frequency distribution of raw immunogenicity score I (N = 11 virus proteins × 69 HLA alleles = 759). (B) Probability-probability (P-P) plot to illustrate deviation from normal distribution.Figure 11.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "For that purpose, we split a given virus antigen (Table 6) to all possible 9-mer (nonamer) AA residue epitopes using a sliding window approach68–70 (Fig. 9) and submitted each epitope to the web-application together with a specific HLA allele (Table 5).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The distribution of I was skewed to the right (Fig. 10A), deviating substantially from a normal distribution (Fig. 10B).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel A",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "Panel B",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "A logarithmic transformation of I made the distribution more symmetric (Fig. 11A) and closer to normal (Fig. 11B).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel B",
        "figure_key": "figure_11"
      }
    ]
  }
]